Renaissance Capital logo

IN8bio Priced, Nasdaq: INAB

Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies.

Industry: Health Care

Latest Trade: $6.46 -0.17 (-2.6%)

First Day Return: 0.0%

Return from IPO: -33.7%

Industry: Health Care

We are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a functional bridge between these two systems to impact tumor killing. In addition to our allogeneic approach, we are able to genetically modify gamma-delta T cells to induce resistance to certain types of chemotherapy, which allows administration during chemotherapy, when a tumor is experiencing maximum stress and is at its most vulnerable state. We are the first company to advance genetically modified gamma-delta T cells into the clinic, leveraging the powerful and naturally occurring anti-cancer properties of these cells to enable their use in combination with therapeutic administration of chemotherapy. We are currently conducting two investigator-initiated Phase 1 clinical trials for both of our lead gamma-delta T cell product candidates: INB-200, for the treatment of newly diagnosed glioblastoma, or GBM, and INB-100, for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation, or HSCT.
more less
IPO News for IN8bio
more
IPO Data
IPO File Date 10/16/2020
Offer Price $10.00
Price Range $10.00 - $12.00
Offer Shares (mm) 4.0
Deal Size ($mm) $40
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/29/2021
Offer Price $10.00
Price Range $10.00 - $12.00
Offer Shares (mm) 4.0
Deal Size ($mm) $40
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2016
Employees 7
Website www.in8bio.com